JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Home・Akciju saraksts・Simulations Plus Inc

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

14.6 0.55

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.23

Max

14.86

Galvenie mērījumi
By Trading Economics
Ienākumi	3.9M 4.5M
Pārdošana	5.9M 24M
EPS	0.35
Dividenžu ienesīgums	0.48
Peļņas marža	18.669
Darbinieki	212
EBITDA	4.9M 7.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+9.89% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.48% 2.24%
Nākamie ieņēmumi	2026. g. 13. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	51M 302M
Iepriekšējā atvēršanas cena	14.05
Iepriekšējā slēgšanas cena	14.6

Ziņu noskaņojums

By Acuity

21%

79%

52 / 348 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. apr. 23:15 UTC

Galvenie ziņu notikumi

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026. g. 27. apr. 23:08 UTC

Peļņas

Galvenie tirgus virzītāji

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026. g. 27. apr. 23:48 UTC

Tirgus saruna

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026. g. 27. apr. 23:42 UTC

Tirgus saruna

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026. g. 27. apr. 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026. g. 27. apr. 23:30 UTC

Tirgus saruna

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026. g. 27. apr. 23:08 UTC

Tirgus saruna

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026. g. 27. apr. 22:42 UTC

Tirgus saruna

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026. g. 27. apr. 22:10 UTC

Peļņas

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026. g. 27. apr. 21:56 UTC

Peļņas

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026. g. 27. apr. 21:44 UTC

Peļņas

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026. g. 27. apr. 21:43 UTC

Peļņas

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. apr. 20:39 UTC

Peļņas

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

9.89% augšup

Prognoze 12 mēnešiem

Vidējais 16 USD 9.89%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

52 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.